The hepatotoxicity of antifungal medications in bone marrow transplant recipients

Clinical Infectious Diseases

Volumn 41, Issue 3, 2005, Pages 301-307

  Fischer, Michael A ^a   Winkelmayer, Wolfgang C ^a   Rubin, Robert H ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; BILIRUBIN; FLUCONAZOLE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CASE-CONTROL STUDIES; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; FLUCONAZOLE; HEPATITIS, TOXIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; RISK FACTORS;

EID: 22544488439     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/431586     Document Type: Article

References (27)

1. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5:55-68.
2. Dictar MO, Maiolo E, Alexander B, Jacob N, Veron MT. Mycoses in the transplanted patient. Med Mycol 2000; 38:251-8.
3. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19:801-8.
4. Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-66.
5. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33:641-7.
6. Geha DJ, Roberts GD. Laboratory detection of fungemia. Clin Lab Med 1994; 14:83-97.
7. Richardson MD, Kokki MH. New perspectives in the diagnosis of systemic fungal infections. Ann Med 1999; 31:327-35.
8. Alexander BD. Diagnosis of fungal infection: new technologies for the mycology laboratory. Transpl Infect Dis 2002; 4:32-7.
9. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
10. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation, a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
11. Winston DJ, Parnatharthi HC, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med 1993; 118:495-503.
12. Denning DW, Lee JY, Hosteller JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole for invasive aspergillosis. Am J Med 1994; 97:135-44.
13. Rex JH, Bennett JE, Sugar AM, et al. A randomized trail comparing fluconazole with amphotericin B for treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
14. Malik IA, Moid I, Aziz Z, Khan S, Suleman M. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 1998; 105:478-83.
15. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-71.
16. Walsh TJ, Himenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
17. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott Williams & Wilkins, 1998.
18. Lindor KD, Fleming CR, Abrams A, Hirschkorn MA. Liver function values in adults receiving total parenteral nutrition. JAMA 1979; 241:2398-400.
19. Lowry SF, Brennan MF. Abnormal liver function during parenteral nutrition: relation to infusion excess. J Surg Res 1979; 26:300-7.
20. Leaseburge LA, Winn NJ, Schloerb PR. Liver test alterations with total parenteral nutrition and nutritional status. JPEN J Patenter Enteral Nutr 1992; 16:348-52.
21. Craig RM, Coy D, Green R, Meersman R, Rubin H, Janssen I. Hepatotoxicity related to total parenteral nutrition: comparison of low-lipid and lipid-supplemented solutions. J Crit Care 1994; 9:111-3.
22. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711-8.
23. Jacobson MA, Hanks DK, Ferrel LD. Fatal acute hepatic necrosis due to fluconazole. Am J Med 1994; 96:188-90.
24. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337:15-21.
25. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002; 35:1273-5.
26. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630-7.
27. Spellberg B, Rieg G, Bayer A, Edwards JE Jr. Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis 2003; 36:1091-3.